What's new - Week 13 2025 (24/Mar - 30/Mar)

Organic molecules of unprecedented size discovered on Mars	Full Article
Scientists detected the longest organic molecules identified to date on Mars, containing up to 12 consecutive carbon atoms, which could exhibit features similar to fatty acids produced on Earth by biological activity.
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates	Full Article
Researchers discussed a potential gene replacement therapy for Dravet Syndrome tested in mice with promising results, alongside updates on Sarepta’s clinical trials and AstraZeneca’s recent activities.
Researchers see breakthrough in efficient biofuel production	Full Article
A collaboration between the University of Cincinnati and Oak Ridge National Laboratory reported significant improvements in biofuel production efficiency.
Enhertu Successor Gets First FDA OK in Breast Cancer	Full Article
The FDA approved a new breast cancer treatment, marking a significant advancement in oncology therapeutics.
YolTech Therapeutics Begins First Trial of In Vivo CRISPR Therapy for Blood Disease	Full Article
YolTech Therapeutics initiated the first clinical trial using in vivo CRISPR gene-editing therapy to treat a blood disorder.
Microbiome May Open Next Chapter in Transplant Diagnostics	Full Article
Emerging preclinical data suggest that microbiome analysis could play a crucial role in improving diagnostics for organ transplant outcomes.
JP Morgan Healthcare Conference Highlights: Oxford Nanopore, 10x Genomics, Bruker, Qiagen	Full Article
Key developments from the JP Morgan Healthcare Conference included product launch plans from companies like Oxford Nanopore and Qiagen.
GRI Bio’s Tazarotene Shows Phase IIa Promise in Idiopathic Pulmonary Fibrosis	Full Article
GRI Bio Inc.’s oral tazarotene demonstrated promising interim safety results in a Phase IIa trial for treating idiopathic pulmonary fibrosis.
Abbott’s Triclip Shows Benefit in Tricuspid Valve Repair Study	Full Article
Two-year results from the TRILUMINATE trial indicated that Abbott Laboratories’ Triclip device effectively reduces hospitalizations for patients undergoing tricuspid valve repair.